Company intelligence / Profile preview
Dynogen Pharmaceuticals, Inc.
Waltham, Massachusetts, United Statesdynogen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company had multiple clinical programs including DDP733 (pumosetrag) for IBS-c which entered Phase 2b trials, DDP225 which showed positive results in Phase 2a for IBS-d with 71% response rate vs 25% for placebo, and DDP200 for overactive bladder. The company was placed in administration in February 2009 after failing to secure financing when clinical data in one program was not sufficiently positive.[1][6][9]
- Therapeutic areas
- GastroenterologyMen's Health
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Evotec OAIAstellas Pharma Inc.
Beyond the preview
Go deeper on Dynogen Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dynogen Pharmaceuticals, Inc..